174 related articles for article (PubMed ID: 15732289)
1. Cyclophosphamide in lupus nephritis.
Houssiau FA
Lupus; 2005; 14(1):53-8. PubMed ID: 15732289
[TBL] [Abstract][Full Text] [Related]
2. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
4. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
[TBL] [Abstract][Full Text] [Related]
5. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
Morović-Vergles J; Galesić K; Dancuo I; Vergles D
Acta Med Croatica; 2004; 58(1):13-7. PubMed ID: 15125388
[TBL] [Abstract][Full Text] [Related]
6. Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study.
Zhang XW; Li C; Ma XX; Zhao JX; An Y; Liu S; Li Y; Li ZG
Clin Rheumatol; 2014 Jul; 33(7):939-45. PubMed ID: 24744152
[TBL] [Abstract][Full Text] [Related]
7. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
8. [Cyclophosphamide therapy in systemic lupus erythematosus].
Backhaus M; Hiepe F
Z Rheumatol; 1997; 56(4):178-89. PubMed ID: 9417758
[TBL] [Abstract][Full Text] [Related]
9. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
[TBL] [Abstract][Full Text] [Related]
11. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
[TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
[TBL] [Abstract][Full Text] [Related]
14. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study.
Fei Y; Wu Q; Zhang W; Chen H; Hou Y; Xu D; Li M; Zhang X; Zhao Y; Zeng X; Zhang F
Clin Exp Rheumatol; 2013; 31(1):62-8. PubMed ID: 22935463
[TBL] [Abstract][Full Text] [Related]
15. Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis.
Seong SS; Choi CB; Yun HR; Kim YJ; Sung YK; Bae SC
Rheumatol Int; 2008 Mar; 28(5):453-8. PubMed ID: 17924111
[TBL] [Abstract][Full Text] [Related]
16. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
18. Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the FCGR2B-FCRLA Locus.
Kim K; Bang SY; Joo YB; Kim T; Lee HS; Kang C; Bae SC
J Rheumatol; 2016 Jun; 43(6):1045-9. PubMed ID: 26980576
[TBL] [Abstract][Full Text] [Related]
19. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
Rivera TL; Belmont HM; Malani S; Latorre M; Benton L; Weisstuch J; Barisoni L; Tseng CE; Izmirly PM; Buyon JP; Askanase AD
J Rheumatol; 2009 Feb; 36(2):298-305. PubMed ID: 19040310
[TBL] [Abstract][Full Text] [Related]
20. Successful pregnancy after cyclophosphamide therapy for lupus nephritis.
Lannes G; Elias FR; Cunha B; Jesus N; Klumb EM; Albuquerque EM; Ribeiro FM
Arch Gynecol Obstet; 2011 Mar; 283 Suppl 1():61-5. PubMed ID: 21331538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
